Trinity Biotech (TRIB) announced that the in-country healthcare product regulatory authority has granted the approval to initiate offshore and outsourced manufacturing of its World Health Organization, WHO, prequalified TrinScreen HIV rapid test. This key approval now enables Trinity Biotech to transition upstream production from its legacy in-house operations to a more cost-effective and scalable outsourced model. Trinity Biotech has now begun manufacturing under this new model, marking a critical milestone in the Company’s transformation strategy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIB:
- Trinity Biotech Gains Approval for PreClara™ Preeclampsia Testing Service
- Trinity Biotech receives approval from NYSDOH to provide PreClara Ratio
- Trinity Biotech Announces Breakthrough in CGM Technology
- Trinity Biotech announces clinical trial results for redesigned CGM sensor
- Trinity Biotech Launches FDA-cleared Preeclampsia Testing Service